Clearmind Medicine (NASDAQ:CMND; FSE:CWYO) announced it has filed an additional patent application with the USPTO for the novel proprietary composition of its MEAI compound for treating metabolic syndrome and obesity. This is part of ongoing collaborations with SciSparc (NASDAQ:SPRC).
The global obesity treatment market size was valued at $15 billion in 2022 and is expected to register a rapid revenue CAGR of 10.0% from 2023 to 2032, as reported by Emergen Research.
In total, Clearmind, in collaboration with SciSparc, has filed twelve other patent applications with USPTO for various proprietary compositions, including for the treatment of alcohol use disorder, cocaine addiction, and obesity and its related metabolic disorders.
Clearmind develops breakthrough treatments for binge behavior and mental health, including alcohol use disorder, binge eating, and depression. The company’s patent family consists of 28 granted patents, and the company has stated its intention to seek additional patents for its compounds whenever warranted.
